FabRx
FabRx Paracetamol_tablets_printed_with_the_Sintratec_Kit
Paracetamol tablets printed with the Sintratec Kit.
FabRx, a research group looking to harness 3D printing for the production of medicine, has invested in Sintratec Selective Laser Sintering (SLS) technology.
The University College London alumni have purchased a second Sintratec Kit, after instant success with their first machine. FabRx says it has found a whole new approach of producing its Printlets after adopting the SLS system.
Printlets can contain varying levels of dosage, be designed so they are easy to swallow, and be produced in different flavours, colours and shapes. They can even contain multiple drugs. The idea is to make medicines more appealing to youngsters and easier to consume for the elderly. It won them the 2017 TCT Show Start-Up Award, and is the result of five years’ worth of research. Towards the end of last year, a Kickstarter campaign was launched in an attempt to fund the company’s efforts as it looked to adapt The Magic Candy Factory’s 3D printer. A few months on, it has reported the successful adoption of another system on the market.
FabRx
FabRx Fabrizio_Fina_in_front_of_the_Sintratec_Kit
Fabrizio Fina of FabRx with the Sintratec Kit system.
FabRx boasts a number of 3D printing technologies, including FDM and SLA as well as SLS, in its lab down in London. The company chose to purchase a Sintratec Kit SLS machine because of its open parameters, wanting to alter the laser speed and material temperature to make fine adjustments as and when necessary. FabRx believe it is the first group in the world to investigate SLS technology to print oral formulations, and after the positive impact the Sintratec Kit has had, is now working to identify a medicine to take advantage of SLS capabilities. A machine that is marketed by Sintratec as a system suitable for prototyping, mechanical engineering, and the production of spare parts, may now also be considered a platform for making medicine.
